174 related articles for article (PubMed ID: 24403123)
21. Cooperation of neurotrophin receptor TrkB and Her2 in breast cancer cells facilitates brain metastases.
Choy C; Ansari KI; Neman J; Hsu S; Duenas MJ; Li H; Vaidehi N; Jandial R
Breast Cancer Res; 2017 Apr; 19(1):51. PubMed ID: 28446206
[TBL] [Abstract][Full Text] [Related]
22. Multiplex quantitative assays indicate a need for reevaluating reported small-molecule TrkB agonists.
Boltaev U; Meyer Y; Tolibzoda F; Jacques T; Gassaway M; Xu Q; Wagner F; Zhang YL; Palmer M; Holson E; Sames D
Sci Signal; 2017 Aug; 10(493):. PubMed ID: 28831019
[TBL] [Abstract][Full Text] [Related]
23. Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness.
Cimmino F; Schulte JH; Zollo M; Koster J; Versteeg R; Iolascon A; Eggert A; Schramm A
Oncogene; 2009 May; 28(19):2015-23. PubMed ID: 19363525
[TBL] [Abstract][Full Text] [Related]
24. Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival.
Vanhecke E; Adriaenssens E; Verbeke S; Meignan S; Germain E; Berteaux N; Nurcombe V; Le Bourhis X; Hondermarck H
Clin Cancer Res; 2011 Apr; 17(7):1741-52. PubMed ID: 21350004
[TBL] [Abstract][Full Text] [Related]
25. BDNF dependence in neuroblastoma.
Feng X; Jiang H; Baik JC; Edgar C; Eide FF
J Neurosci Res; 2001 May; 64(4):355-63. PubMed ID: 11340642
[TBL] [Abstract][Full Text] [Related]
26. Expression of trkB in human neuroblastoma in relation to MYCN expression and retinoic acid treatment.
Edsjö A; Lavenius E; Nilsson H; Hoehner JC; Simonsson P; Culp LA; Martinsson T; Larsson C; Påhlman S
Lab Invest; 2003 Jun; 83(6):813-23. PubMed ID: 12808116
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of TrkB Expression and Signaling by Valproic Acid and Other Histone Deacetylase Inhibitors.
Dedoni S; Marras L; Olianas MC; Ingianni A; Onali P
J Pharmacol Exp Ther; 2019 Sep; 370(3):490-503. PubMed ID: 31308194
[TBL] [Abstract][Full Text] [Related]
28. The TrkB+ cancer stem cells contribute to post-chemotherapy recurrence of triple-negative breast cancers in an orthotopic mouse model.
Yin B; Ma ZY; Zhou ZW; Gao WC; Du ZG; Zhao ZH; Li QQ
Oncogene; 2015 Feb; 34(6):761-70. PubMed ID: 24531713
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model.
MacFarland SP; Naraparaju K; Iyer R; Guan P; Kolla V; Hu Y; Tan K; Brodeur GM
Mol Cancer Ther; 2020 Mar; 19(3):920-926. PubMed ID: 31871269
[TBL] [Abstract][Full Text] [Related]
30. Targeting Akt to increase the sensitivity of neuroblastoma to chemotherapy: lessons learned from the brain-derived neurotrophic factor/TrkB signal transduction pathway.
Li Z; Thiele CJ
Expert Opin Ther Targets; 2007 Dec; 11(12):1611-21. PubMed ID: 18020981
[TBL] [Abstract][Full Text] [Related]
31. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
Iyer R; Wehrmann L; Golden RL; Naraparaju K; Croucher JL; MacFarland SP; Guan P; Kolla V; Wei G; Cam N; Li G; Hornby Z; Brodeur GM
Cancer Lett; 2016 Mar; 372(2):179-86. PubMed ID: 26797418
[TBL] [Abstract][Full Text] [Related]
32. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways.
Cheng J; Fan YH; Xu X; Zhang H; Dou J; Tang Y; Zhong X; Rojas Y; Yu Y; Zhao Y; Vasudevan SA; Zhang H; Nuchtern JG; Kim ES; Chen X; Lu F; Yang J
Cell Death Dis; 2014 Feb; 5(2):e1079. PubMed ID: 24556694
[TBL] [Abstract][Full Text] [Related]
33. The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan.
Zage PE; Graham TC; Zeng L; Fang W; Pien C; Thress K; Omer C; Brown JL; Zweidler-McKay PA
Cancer; 2011 Mar; 117(6):1321-91. PubMed ID: 20960503
[TBL] [Abstract][Full Text] [Related]
34. Oral RKS262 reduces tumor burden in a neuroblastoma xenograft animal model and mediates cytotoxicity through SAPK/JNK and ROS activation in vitro.
Singh RK; Dorf L; DeMartino A; Illenye S; Koto K; Currier EA; Ashikaga T; Kim KK; Brard L; Sholler GL
Cancer Biol Ther; 2011 Jun; 11(12):1036-45. PubMed ID: 21532338
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin-induced cytotoxicity is blocked by brain-derived neurotrophic factor activation of TrkB signal transduction path in neuroblastoma.
Jaboin J; Hong A; Kim CJ; Thiele CJ
Cancer Lett; 2003 Apr; 193(1):109-14. PubMed ID: 12691830
[TBL] [Abstract][Full Text] [Related]
36. BDNF: An Oncogene or Tumor Suppressor?
Radin DP; Patel P
Anticancer Res; 2017 Aug; 37(8):3983-3990. PubMed ID: 28739680
[TBL] [Abstract][Full Text] [Related]
37. NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis.
Shi Y; Ma IT; Patel RH; Shang X; Chen Z; Zhao Y; Cheng J; Fan Y; Rojas Y; Barbieri E; Chen Z; Yu Y; Jin J; Kim ES; Shohet JM; Vasudevan SA; Yang J
Cell Death Dis; 2015 Aug; 6(8):e1841. PubMed ID: 26247726
[TBL] [Abstract][Full Text] [Related]
38. Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells.
Matsumoto K; Wada RK; Yamashiro JM; Kaplan DR; Thiele CJ
Cancer Res; 1995 Apr; 55(8):1798-806. PubMed ID: 7712490
[TBL] [Abstract][Full Text] [Related]
39. The inhibition of BDNF/TrkB/PI3K/Akt signal mediated by AG1601 promotes apoptosis in malignant glioma.
Yin H; Jiang Y; Zhang Y; Ge H; Yang Z
J Cell Biochem; 2019 Nov; 120(11):18771-18781. PubMed ID: 31219215
[TBL] [Abstract][Full Text] [Related]
40. In Vitro Sensitivity Profiling of Neuroblastoma Cells Against A Comprehensive Small Molecule Kinase Inhibitor Library to Identify Agents for Future Therapeutic Studies.
Singh A; Meier-Stephenson V; Jayanthan A; Narendran A
Curr Cancer Drug Targets; 2017; 17(6):569-584. PubMed ID: 27875952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
